12:46 AM EDT, 10/15/2026 (MT Newswires) -- Pila Pharma (PILA.ST) began the execution phase of its PP-CT04 clinical study of XEN-D0501 as a treatment for people with obesity. The clinical-stage biotechnology company said Wednesday the study will assess the safety, tolerability, absorption, and efficacy of the oral TRPV1 antagonist in obesity. The two-part randomized, double-blind, placebo-controlled study will take 12 weeks. The dosing of the first two trial participants marked the start of the first part, which will involve eight participants in total.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.